Vaxart Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Vaxart şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-40.8%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-40.8%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: VXRT * şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: VXRT * şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Vaxart Piyasaya Karşı Temettü Getirisi

VXRT * temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (VXRT *)	n/a
Pazarın Alt %25'i (MX)	0%
Pazarın En İyi %25'i (MX)	0%
Sektör Ortalaması (Biotechs)	0%
Analist tahmini (VXRT *) (3 yıla kadar)	n/a

Önemli Temettü: VXRT * şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, VXRT * şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: VXRT * şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: VXRT * herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Vaxart Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Vaxart, Inc. to Report Q3, 2024 Results on Nov 13, 2024

Vaxart, Inc. Announces Initiation of Sentinel Cohort for Phase 2B Study Evaluating its Covid-19 Oral Pill Vaccine Candidate

Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of Its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for Hpv-Related Cervical Dysplasia

Second quarter 2024 earnings released: US$0.089 loss per share (vs US$0.16 loss in 2Q 2023)

Vaxart, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Vaxart Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2) for Continued Listing on the Nasdaq Capital Market

Independent Director recently bought Mex$250k worth of stock

High number of new and inexperienced directors

Vaxart, Inc. Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

First quarter 2024 earnings released: US$0.14 loss per share (vs US$0.19 loss in 1Q 2023)

Vaxart, Inc. to Report Q1, 2024 Results on May 13, 2024

High number of new and inexperienced directors

Vaxart, Inc., Annual General Meeting, Jun 11, 2024

Vaxart, Inc. to Report Fiscal Year 2023 Results on Mar 14, 2024

Vaxart, Inc. Announces Chief Executive Officer Changes

Less than half of directors are independent

Less than half of directors are independent

Nasdaq Notifies Vaxart's Eligibility for an Additional 180-Day Compliance Period, or Until July 15, 2024, to Regain Compliance with the Bid Price Requirement

Vaxart, Inc. Announces CEO Changes

Vaxart, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Vaxart, Inc. Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

Vaxart Doses First Subject in Phase 1 Trial of its Norovirus Vaccine Candidate in Lactating Mothers

Vaxart, Inc. to Report Q3, 2023 Results on Nov 02, 2023

New minor risk - Market cap size

High number of new and inexperienced directors

Vaxart Announces Topline Data from the Phase 2 Challenge Study of Its Monovalent Norovirus Vaccine Candidate

Vaxart, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Vaxart Receives Written Notice from the Listing Qualifications Department of the Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price Requirement

High number of new and inexperienced directors

Vaxart, Inc. Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate

High number of new and inexperienced directors

Vaxart, Inc.(NasdaqCM:VXRT) dropped from Russell 2000 Dynamic Index

Vaxart, Inc. Announces Last Subject Dosed in Phase 2 Trial of Its Bivalent Norovirus Candidate, and All Subjects Challenge Study of Monovalent Norovirus Candidate

First quarter 2023 earnings released: US$0.19 loss per share (vs US$0.20 loss in 1Q 2022)

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Vaxart, Inc. Doses First Subject in the Phase 2 Clinical Trial of Its Bivalent Norovirus Candidate

Director recently bought Mex$294k worth of stock

Vaxart, Inc. Names Phillip Lee as Chief Financial Officer

High number of new and inexperienced directors

Vaxart, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Vaxart, Inc. Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate

Vaxart, Inc. Appoints Ray Stapleton as Chief Technology Officer

Vaxart, Inc. Announces Board Changes

Vaxart, Inc. Appoints W. Mark Watson to Its Board of Directors

Vaxart, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Vaxart, Inc. Publishes Clinical Data Suggesting its Oral COVID-19 Pill Vaccine Candidate Induces Long-Lasting Mucosal Immune Responses that are Highly Cross-Reactive

High number of new and inexperienced directors

Key Executive recently bought Mex$322k worth of stock

High number of new and inexperienced directors

Vaxart, Inc. Presents New Preclinical Data Demonstrate Two of it's COVID-19 Vaccine Candidates Protect Against Omicron

Vaxart Reports Positive Preliminary Data from the Phase 1b Trial of its Oral Norovirus Vaccine Candidates in Elderly Adults

High number of new and inexperienced directors

Vaxart Announces the Publication of Studies in the Peer-Reviewed Journal Science Translational Medicine That Suggest Mucosal Immunization Could Decrease SARS-CoV-2 Transmission

Vaxart, Inc. Announces Management Changes

First quarter 2022 earnings released: US$0.20 loss per share (vs US$0.14 loss in 1Q 2021)

No longer forecast to breakeven

High number of new and inexperienced directors

Margaret Echerd Notifies as Senior Vice President and Principal Accounting Officer of Vaxart, Inc, Effective as of May 5, 2022

High number of new and inexperienced directors

Vaxart, Inc. Appoints Edward B. Berg as Senior Vice President and General Counsel

High number of new and inexperienced directors

Forecast to breakeven in 2024

Forecast to breakeven in 2024

High number of new and inexperienced directors

High number of new and inexperienced directors

Vaxart to Test Cross-Reactivity of Its Covid-19 Oral Tablet Vaccine Against Omicron

High number of new and inexperienced directors

Vaxart, Inc. (NasdaqCM:VXRT) acquired KindredBio's manufacturing equipment and GMP manufacturing facility in California from Kindred Biosciences, Inc.

No longer forecast to breakeven

High number of new and inexperienced directors

High number of new and inexperienced directors

Third quarter 2021 earnings released: US$0.14 loss per share (vs US$0.075 loss in 3Q 2020)

Third quarter 2021 earnings released: US$0.14 loss per share (vs US$0.075 loss in 3Q 2020)